Acoustic prepulse inhibition (PPI) is considered an important biomarker in animal studies of psychosis and a number of psychiatric conditions. Nicotine has been shown to improve acoustic PPI in some animal strains and in humans. However, there is little data on effects of nicotine on acoustic PPI in schizophrenia patients using a double-blind, placebo-controlled study design. The primary aim of the current study was to test the effect of nicotine nasal spray on acoustic PPI in schizophrenia patients. The secondary aim was to test nicotine effect on prepulse facilitation (PPF). The study included 18 schizophrenia patient smokers and 12 healthy control smokers, tested in a double-blind, placebo-controlled, crossover, randomized design immediately after nicotine or saline placebo nasal sprays. PPI was tested using 120 ms prepulse-pulse interval. PPF was tested using 4500 ms prepulse-pulse interval. The results showed a significant main effect of drug on PPI in that nicotine improved PPI compared to placebo (p ¼ 0.008) with no drug by diagnosis interaction (p ¼ 0.90). Improvement in PPI in response to nicotine was significantly correlated with the baseline severity of clinical symptoms (r ¼ 0.59, p ¼ 0.02) in patients. There was no significant drug or drug by diagnosis interaction for the 4500 ms prepulse-pulse interval condition. However, nicotine improved inhibition in a subgroup of subjects exhibiting PPF (p ¼ 0.002). In conclusion, the findings confirmed that nicotine transiently improves acoustic PPI in schizophrenia patients. Additionally, schizophrenia patients with more clinical symptoms may have benefited more from nicotinic effect on PPI.
INTRODUCTION
Prepulse inhibition (PPI) is a measure of the suppression of the startle response when a less intense stimulus precedes a startling stimulus by a short interval. PPI has been found to be abnormal in schizophrenia patients and in their relatives, and appears to be under significant genetic control (Braff and Geyer, 1990; Cadenhead et al, 2000; Anokhin et al, 2003; Kumari and Postma, 2005; Hong et al, 2007) . PPI has increasingly been used as a surrogate index of psychosis in animal models (Swerdlow et al, 1994; Braff et al, 2001 ). However, PPI abnormality is not specific to schizophrenia or psychosis since it is also associated with several other psychiatric conditions including stress, bipolar disorder with psychotic features, panic disorder, obsessive-compulsive disorder, dementia, and autism (Grillon and Davis, 1997; Perry et al, 2001 Perry et al, , 2007 Ludewig et al, 2002; Hoenig et al, 2005; Ueki et al, 2006) .
Animal studies have shown that nicotine enhances acoustic PPI in some rodent strains (Acri, 1994; Curzon et al, 1994; Acri et al, 1995; Faraday et al, 1999; Schreiber et al, 2002; Spielewoy and Markou, 2004) ; an effect thought to be mediated by nicotinic acetylcholine receptors (nAChRs) (Schreiber et al, 2002; Suemaru et al, 2004) . However, other studies have shown no effect, or even the opposite effect (Decker et al, 1997; Faraday et al, 1999; Mirza et al, 2000; Schreiber et al, 2002) . Several studies in healthy humans have generally affirmed the nicotinic enhancement of PPI (Kumari et al, 1996; Della Casa et al, 1998; Duncan et al, 2001) , but the opposite effect has also been reported in studies using cigarettes with high nicotine content (Hutchison et al, 2000) .
Investigators have hypothesized that the disproportionately high rate of smoking in schizophrenia is because nicotine reverses the disease-related deficits, including the PPI deficit, in schizophrenia patients (Chambers et al, 2001; Kumari and Postma, 2005) . In some rodent strains, nicotine blocks PPI deficit induced by agents that modulate neurotransmitter systems putatively related to schizophrenia pathophysiology. These agents include the NMDA antagonist PCP and dopamine agonist apomorphine (Spielewoy and Markou, 2004; Suemaru et al, 2004; Andreasen et al, 2006) . However, nicotinic effect on PPI in schizophrenia patients has not been sufficiently studied.
One naturalistic study showed that in schizophrenia patient smokers, smoking immediately before testing had more PPI compared to patient smokers who did not smoke immediately before the testing and nonsmoker patients (Kumari et al, 2001) . Also, PPI was found higher in smoker patients compared to nonsmoker patients (Swerdlow et al, 2006) . A double-blind, placebo-controlled study using tactile PPI showed that subcutaneous nicotine injection improved PPI in patients in 30 ms interstimulus interval (ISI), but not in 120 ms ISI (Postma et al, 2006) . Another study showed that acoustic PPI in schizophrenia patients was impaired by acute abstinence from smoking and enhanced by smoking reinstatement, an effect that appeared to be mediated by central nAChRs (George et al, 2006) . This current study aimed to test nicotine effects on acoustic PPI in schizophrenia patients using a standard double-blind, placebo-controlled design. Nicotine nasal spray has the advantage of fast central access, which effectively mimics the effect of smoking (Johansson et al, 1991) , while allowing a standard double-blind design. We also examined the effects of nicotine on prepulse facilitation (PPF), which is measured when the interval between prepulse and pulse is sufficiently separated. This facilitation with longer ISI is thought to be due to an activating effect related to orienting or attention allocation (Graham, 1975) . The rationale for including PPF was based on observations that nicotine nasal spray improved spatial organization and attention in schizophrenia patients (Smith et al, 2002 (Smith et al, , 2006 , and that PPF has been reported to be impaired in schizophrenia patients and their relatives (Wynn et al, 2004) .
MATERIALS AND METHODS

Subjects
The University of Maryland IRB-approved written informed consent was obtained from each subject. Subjects were required to be 18-60 years of age. Schizophrenia patients were recruited from the Maryland Psychiatric Research Center outpatient clinics and the neighboring community clinics. Patients were individuals with schizophrenia based on Structured Clinical Interview for DSM-IV (SCID-IV), who had no change in their antipsychotic medications during the 2 weeks prior to the beginning of the experiments and had no exacerbation of psychotic symptoms. Healthy volunteers were recruited through media advertisements. These subjects underwent SCID for DSM-IV Axis I and DSM-IV personality disorders interviews. Subjects with Axis I diagnosis or Cluster A personality diagnoses were excluded from the healthy control group. The healthy control subjects had no family history of psychosis in two generations based on family history research diagnostic criteria. Additional exclusion criteria included substance dependence within the past 6 months or current substance abuse and major medical and neurological conditions including history of strokes and head injury. All subjects were current cigarette smokers reporting five or more cigarettes per day. Their smoking history and addiction severity are presented in Table 1 .
Twenty-four schizophrenia and 18 healthy control subjects completed both the nicotine and placebo arms of the PPI study; 25.0% of the patients and 33.3% of the controls were nonresponders to startling sounds based on published criteria (Hong et al, 2007) . The rates of nonresponders were similar to those reported in the literature (eg Braff and Geyer, 1990 ); and were not statistically significant between the two groups (w 2 ¼ 1.18, p ¼ 0.28). The number of subjects included in data analyses was 18 patients and 12 controls. Two patients were on first-generation antipsychotic medications, two were not on antipsychotic medications, and the remaining were on second-generation antipsychotic medications (seven on clozapine, three on aripiprazole, two on olanzapine, one on ziprasidone, and one on risperidone). A toxicology screen prior to the study verified abstinence from controlled substances.
Design
This was a double-blind, placebo-controlled, crossover study comparing nicotine vs saline nasal spray on acoustic PPI. The nasal spray bottles for nicotine and saline had identical appearance. The experimental design was to test two independent tasks, a PPI task and an eye-tracking task (data not reported here). All subjects were allowed to maintain normal smoking routine and then were restrained from smoking for 2 h prior to testing. When subjects were ready to be tested in the laboratory, they were given 1 mg nicotine (Nicotrol NS, Pharmacia & Upjohn, one spray of 0.5 mg to each of the nostrils) or equivalent amount of saline sprays, were given 2-3 min for the initial adverse mucosal stimulus effect to subside, and were tested for 20 min. The absorption half-life of nicotine nasal spray is about 3 min, with plasma level peaking at 4-15 min (PDR Nicotrol NS drug information). Each task (PPI or eye tracking) was designed to last about 20 min, therefore testing occurred in the 20-30 min window after drug administration. This time overlapped with the peak and transient plateau of the nicotine level using nasal spray delivery (Johansson et al, 1991) . In treatment arm 1 (nicotine or saline), all subjects were first tested on the eye-tracking measure for 20 min following administration of 1 mg of nicotine (or placebo). Next, they rested for B30 min (no smoking allowed), then received a second dose of the same drug (nicotine or placebo, 1 h after the first spray), and then were tested for PPI. The treatment arm 1 was then concluded. There was an interval between treatment arm 1 and arm 2, which had no time restriction and the subjects were allowed to smoke as needed. To start the second treatment arm, subjects were to smoke the last cigarette and again refrain from smoking for 2 h. The procedures described in the first treatment arm were repeated with the second drug (saline or nicotine) with the order of the tasks always being eye tracking followed by the PPI test. The order of drugs was randomized and counterbalanced across subjects. Therefore, PPI testing occurred during the 3-3.5 h window after the last cigarette. Most nicotine withdrawal effects begin 6-12 h after the last cigarette, but mild symptoms can start as early as 4 h (Hughes et al, 1994) . We therefore limited the abstinence time to within 4 h to minimize potential confounds from withdrawal. This is important in the context of PPI because nicotine withdrawal state is known to reduce PPI in some subjects (eg Kumari et al, 1996; Kumari and Gray, 1999) . The half-life of 1 mg nasal spray is about 1 h. Therefore, the first task (eye tracking) was performed after 1 mg of nicotine, while PPI was tested under slightly higher level of nicotine (1 mg plus the remaining nicotine level from the first spray). This dose difference between the two tasks was not considered critical since the study design was to allow testing of two independent hypotheses and not to compare the two tasks. Subjects were not allowed to smoke in the 3.5-h window from the last cigarette to the end of PPI testing (2 h after last cigarette + 1 h after first spray for eye tracking + 30 min for second spray and PPI testing). During this period a staff monitored abstinence.
Measurement of Clinical Symptoms
Baseline clinical symptoms in patients were measured by the 20-item brief psychiatric rating scale (BPRS) using 1-7 scores on each item. The baseline severity of nicotine addiction was assessed by Fagerstrom test for nicotine dependence (Heatherton et al, 1991) . These baseline clinical symptom evaluations were carried out when subjects were smoking ad lib. To monitor potential side effects and withdrawal symptoms on dependent measures, the Minnesota Nicotine Withdrawal ScaleFself-report version (MNWS) for measuring total withdrawal symptoms, a 10-question self-reported questionnaire for smoking urges (QSU) for focused measurement on craving, and a nicotine nasal spray side effect self-report checklist were administered after each PPI testing.
Measurement of Prepulse Inhibition
The recording methods were previously described (Hong et al, 2007) . Briefly, the orbicularis oculi electromyographic (EMG) activity was recorded from the right eye. The EMG recording was processed off-line with a 100 Hz high-pass filter and baseline correction using 100 ms prestimulus baseline. The acoustic stimuli were delivered via headphones. A session started with a 3-min acclimation period with 70 dB white noise. Startling pulse-alone trials contained 116 dB white noise lasting 40 ms. The prepulse-pulse trials contained a 20 ms, 80 dB white noise prepulse, or 10 dB above the background noise. The first three startle responses were discarded. After the first 3 trials, the test included 18 pulsealone trials, 12 prepulse-pulse trials with 120 ms ISI for PPI, and 12 trials with 4500 ms ISI for PPF (Wynn et al, 2004) . Intertrial intervals varied from 12 to 20 s. These trials were evenly divided into two blocks, and were randomized within each block. Peak response amplitude was calculated by the difference between the most positive peak and most negative trough in a 20-150 ms window after pulse onset. PPI/PPF was calculated for each ISI condition as percent suppression in response amplitudes (PPI/PPF (%) ¼ (startle-alone prepulsepulse condition)/startle alone Â 100). A negative value refers to facilitation. During measurements subjects were told to relax and keep their eyes open.
Statistical Analysis
Demographic information between the two groups was compared using ANOVA. Within-subject comparisons of nicotine vs placebo on withdrawal symptoms and drug side effects were carried out by paired t-tests. PPI data were analyzed by repeated measures ANOVA with GreenhouseGeisser adjustments, where the group (patients vs controls) was between subject factors and the session (nicotine vs placebo) was the within-subject factors. The analyses were repeated for PPF. Exploratory analysis of nicotine effect on different blocks was done by adding block as a second within-subject factor. Pearson's correlations were used to test the relationship of clinical and demographic characteristics and nicotinic effect on PPI, as measured by the change of PPI between nicotine vs saline conditions.
RESULTS
Demographics and Nicotine Addiction Parameters
There were no significant differences in the demographic characteristics between schizophrenia patients and healthy controls (Table 1 ). There were no significant differences in smoking severity between patients and controls as measured by Fagerstrom test for nicotine dependence total score (Table 1) . Subjects (combined sample) reported significantly higher number of side effects after nicotine compared to saline nasal sprays (mean±SD: 5.1±2.5 vs 2.3 ± 2.5; t ¼ 6.16, po0.001), suggesting that the saline sprays did not mimic the full spectrum of the nicotine nasal spray side effects. Fagerstrom total score was significantly correlated with MNWS and QSU total scores in both nicotine and placebo conditions (all rX0.35, all pp0.04), suggesting that subjects with more severe nicotine addiction experienced more withdrawal and craving. However, repeated measures ANOVA on MNWS showed no significant drug (p ¼ 0.78) or diagnosis (p ¼ 0.28) main effects (patients: 9.2 ± 5.2 vs 9.6 ± 6.4; controls: 12.6 ± 7.0 vs 11.6 ± 6.1; in nicotine vs placebo conditions, respectively). Similarly, QSU showed no significant drug (p ¼ 0.91) or diagnosis (p ¼ 0.15) effects (patients: 16.9±8.1 vs 16.6±6.3; controls: 13.1 ± 6.3 vs 13.1 ± 6.3; in nicotine vs placebo conditions, respectively). These self-reports showed that subjects did not have significant differences in withdrawal or craving symptoms between nicotine and placebo conditions. Patients and controls also did not significantly differ in their withdrawal or craving symptoms.
Nicotinic Effect on PPI
There were significant main effects of drug (F 1,28 ¼ 8.13, p ¼ 0.008) and a trend toward significance in diagnosis (p ¼ 0.052) but no significant drug by diagnosis interaction (p ¼ 0.90) (Figure 1, left) . To test nicotinic effects on pulsealone response amplitude and prepulse-pulse response amplitude, repeated measures ANOVA was carried out by including stimulus type and drug as two within-subjects factors. There were significant main effects of stimulus type (F 1,28 ¼ 21.58, po0.001) and drug (p ¼ 0.019), but no significant effect of diagnosis (p ¼ 0.62). However, there was a significant stimulus type by diagnosis interaction (p ¼ 0.018). Post hoc tests showed that there was a significant drug effect on pulse-alone startle response amplitude (F 1,28 ¼ 6.64, p ¼ 0.02), but not drug by diagnosis interaction (p ¼ 0.77) or diagnosis main effect (p ¼ 0.79) (Figure 1 , middle). For prepulse-pulse response amplitude, there was no significant main effect of drug (p ¼ 0.16), diagnosis (p ¼ 0.44), or interaction (p ¼ 0.37) (Figure 1, right) . Finally, there was no significant effect of drug, diagnosis, or interaction on peak response latencies (all pX0.20).
Exploratory analysis on PPI blocks using drug and block as two within-subjects factors showed that there were significant main effects of drug (F 1,28 ¼ 4.26, p ¼ 0.05), block (p ¼ 0.03), and diagnosis (p ¼ 0.03). However, there was no block by drug (p ¼ 0.22) or block by diagnosis (p ¼ 0.84) interaction, suggesting that dividing the testing period into blocks did not meaningfully affect the findings on nicotine vs placebo or patient vs control comparisons.
Clinical Symptoms and Nicotinic Effect on PPI
To understand the clinical implication of nicotinic effect on PPI, we examined the relationship of baseline clinical symptoms as measured by BPRS and nicotinic effect on PPI (change of PPI between nicotine vs placebo conditions) in schizophrenia patients. There was a significant correlation between change of PPI by nicotine and BPRS total score (r ¼ 0.59, p ¼ 0.016). For the BPRS factor scores, correlation coefficients were thought disorder (r ¼ 0.43, p ¼ 0.09), withdrawal (r ¼ À0.20, p ¼ 0.47), anxiety (r ¼ 0.71, p ¼ 0.002), activation symptoms (r ¼ À0.19, p ¼ 0.47), and psychosis (r ¼ 0.47, p ¼ 0.07). BPRS total score was not significantly correlated to Fagerstrom score (r ¼ 0.33, p ¼ 0.23) or MNWS and QSU withdrawal/craving scores in either nicotine or placebo conditions (all rp0.28 in absolute values, all pX0.37). Duncan et al (2006) reported that for medicated schizophrenia patients, there were no significant correlations between PPI and BPRS total scores or any subscales. For unmedicated patients, there were significant correlations of PPI and BPRS total symptoms and positive symptoms. This raised the possibility that the observed significant correlation might be due to medication/no medication conditions, or might even be driven by a specific medication(s). Removing the two subjects not on antipsychotic medications resulted in a correlation between nicotine effect on PPI and BPRS of r ¼ 0.60, p ¼ 0.024 (as compared to r ¼ 0.59, p ¼ 0.016 for all patients). Therefore, the significant correlation was present regardless whether the unmedicated patients were included. This suggests that the correlation between symptom severity and nicotinic effect on PPI was not related to medication vs no medication conditions. With regard to specific medications, only the clozapine group (n ¼ 7) was large enough to be meaningful in exploring the correlation between BPRS score and nicotinic effect on PPI. The correlation coefficient (r ¼ 0.65, n ¼ 7, p ¼ 0.11) in the clozapine group was similar to the correlation coefficient obtained in the entire group.
Nicotine Addiction Severity and Nicotinic Effect on PPI
We also noted that Fagerstrom total score was significantly correlated with nicotinic effect on PPI in patients (r ¼ 0.60, p ¼ 0.018). To determine whether the significant correlation Figure 1 Effects of nicotine on prepulse inhibition (PPI). Significant main effect of nicotine was found on percent PPI (left), pulse-alone startle response amplitude (middle), but not prepulse-pulse response amplitude (right). *po0.05; **po0.01 for a main effect of drug.
in patients was a by-product of withdrawal symptoms, we compared nicotinic effect on PPI with reported withdrawal symptoms. There were no significant correlations between change in PPI and MNWS placebo condition (r ¼ 0.22, p ¼ 0.44), MNWS nicotine condition (r ¼ 0.50, p ¼ 0.08), QSU placebo condition (r ¼ 0.11, p ¼ 0.68), or QSU nicotine condition (r ¼ 0.06, p ¼ 0.86). This suggests that the significant correlation between nicotinic effect on PPI and addiction severity in schizophrenia patients cannot be entirely driven by withdrawal symptoms. There was no significant correlation between the Fagerstrom score and change of PPI in the controls (r ¼ 0.07, p ¼ 0.82).
Gender and Nicotinic Effect on PPI
Gender has been found to play an important role in PPI (Swerdlow et al, 1999) and in nicotine's effect on PPI (Faraday et al, 1999; Della Casa et al, 1998) . We examined this potential effect by adding gender as a between-subjects factor in the repeated measures ANOVA. We continued to observe the significant main effects of drug (F 1,26 ¼ 12.68, p ¼ 0.001) and diagnosis (p ¼ 0.02). There was no main effect of gender (p ¼ 0.65). There was a significant drug by gender interaction (p ¼ 0.03), but no gender by drug by diagnosis interaction (p ¼ 0.56). Post hoc tests of nicotinic effect on PPI (calculated as the change in PPI between nicotine and placebo conditions) showed that nicotine had stronger effect on female patients compared to male patients (p ¼ 0.03).
Nicotinic Effect on PPF
There was no significant effect of drug (F 1,28 ¼ 2.12, p ¼ 0.16), diagnosis (p ¼ 0.51), or drug by diagnosis interaction (p ¼ 0.80) on percent inhibition during the 4500 ms ISI condition. However, it was clear that many subjects did not exhibit PPF (percent inhibition less than 0) under this condition (Figure 2, left) . This was unexpected since we adopted this condition based on previous findings of eliciting PPF under this ISI (Wynn et al, 2004) . We conducted an exploratory analysis by dividing subjects who showed PPF (percent inhibition o0) vs subjects who did not show PPF (percent inhibition X0) during placebo condition. In subjects who showed PPF, there was a significant effect of drug (F 1,10 ¼ 16.77, p ¼ 0.002) and diagnosis (p ¼ 0.02), with no significant drug by diagnosis interaction (p ¼ 0.14) on percent inhibition during the 4500 ms, suggesting that nicotine enhanced inhibition rather than facilitation (Figure 2, middle) . For subjects who did not exhibit PPF, there were no significant effects of drug (F 1,16 ¼ 1.64, p ¼ 0.22) and diagnosis (p ¼ 0.43), or drug by diagnosis interaction (p ¼ 0.66) (Figure 2, right) . To guard against the potential 'regression to the mean' effect, we repeated the above analyses by dividing subjects who showed PPF vs no PPF during nicotine condition, and found similar effect of nicotine in increasing inhibition (data not shown). Given the small number of subjects showing PPF, correlation analyses between PPF and clinical scales were not carried out.
DISCUSSION
The primary findings of the study were that nicotine nasal spray increased PPI compared to saline placebo nasal spray in schizophrenia patients, and that the extent of improvement in PPI in response to nicotine in schizophrenia patients was significantly correlated with the baseline severity of clinical symptoms. There was no group by drug interaction, indicating that this effect was not specific to diagnosis. This suggests that the nicotine-induced transient enhancement on PPI in schizophrenia patients was not likely due to medications that patients were taking. Previous studies have also demonstrated that nicotine enhances PPI in nonsmoker controls, which supports the conclusion that the nicotinic effect on PPI is not simply to reverse the effect of nicotine withdrawal, but rather it has an impact on the mechanism of PPI (Kumari et al, 1997; Duncan et al, 2001; Postma et al, 2006) .
To our knowledge, this appears to be the first reported double-blind, placebo-controlled study to test nicotine effect on acoustic PPI in schizophrenia patients. The results were consistent with smoking challenge studies on acoustic PPI (George et al, 2006) and data from a double-blind, placebo-controlled subcutaneous nicotine challenge on tactile PPI (Postma et al, 2006) . All of these studies showed significant enhancement of PPI by nicotine in schizophrenia patients. One of the questions raised by the previous studies was whether the beneficial effects observed with nicotine Figure 2 Effects of nicotine on prepulse facilitation (PPF). There was a lack of significant effect of nicotine on PPF in either group (left). For subjects who exhibited PPF, there was a significant effect of nicotine (middle). No significant effect on PPF was found in subjects who did not exhibit PPF (right). **po0.01 for a main effect of drug.
administration was a result of reversal of the nicotine withdrawal effects on PPI (Kumari et al, 1996; Della Casa et al, 1998; George et al, 2006) . Findings from our study addressed this issue by limiting the abstinence period to 3.5 h before withdrawal symptoms become evident. Our strategy appeared to be effective since we did not find differences in withdrawal or craving symptoms between nicotine vs placebo conditions. One limitation of the study is that the saline nasal spray was less effective in mimicking the side effects of nicotine, as evident by significantly less reported number of side effects from saline sprays. This may have reduced the validity of the double-blind design.
The nicotine effect on PPI was primarily on the startlealone response (Figure 1, middle panel) , which was consistent with several previous reports in humans and rodents (Acri et al, 1995; Faraday et al, 1999; Duncan et al, 2001 ). We did not find significant nicotinic effect in reducing response amplitude in prepulse-pulse trials. This raises the question whether nicotine effect on PPI is primarily an activating effect on the startle response rather than an enhancement of inhibitory functions. We do not think this is the case because the activating effect should occur for both pulse and prepulse-pulse trials, thus the percentage inhibition relative to the startle response during the pulse-alone condition is the best and valid measure of PPI. This measure was significantly increased under nicotine condition.
The significant correlation (Pearson's correlation coefficient r ¼ 0.59) between nicotine's effect on PPI and BPRS score suggests that patients with more clinical symptoms benefited more from the transient enhancement of PPI by nicotine. This correlation was not likely an artifact of nicotine addiction or withdrawal symptom since the BPRS was carried out while subjects were allowed smoking, and the nicotine addiction or withdrawal measures did not significantly correlate with BPRS. We did not expect that BPRS would change over a single nasal spray treatment; therefore we did not assess BPRS after the nasal sprays. This limited our ability to assess the predictive value of PPI response to nicotinic and clinical improvement, which would require assessment of BPRS before and after treatment. However, this finding is nevertheless exciting and suggests that PPI maybe a sensitive and clinically relevant biomarker in identifying new nicotinic nAChR subtype agents that may have clinical implications. BPRS total score is comprised of a number of clinical symptoms and the correlation were modest for anxiety, psychosis, and thought disorder subscale scores. It raises the possibility that PPI enhancement by nicotine may be associated with the severity of these clinical symptoms.
Nicotinic effect on PPI was also correlated with nicotine addiction severity (as measured by Fagerstrom total score; r ¼ 0.60) in schizophrenia patients. The effect appeared unique to schizophrenia patients and was not present in healthy controls. This finding supports the argument that high rate of nicotine addiction in schizophrenia patients does not necessarily share the underlying nicotine addiction-related factors in nonschizophrenia individuals, but might be related to certain core schizophrenia-related biological deficits (Chambers et al, 2001; Kumari and Postma, 2005) . We note that this correlation is not mediated by the severity of withdrawal or craving symptoms in patients with more severe addiction because the nicotineinduced change in PPI did not significantly correlate with these symptoms.
A novel finding from this study was that nicotine might have reversed the PPF to inhibition of the startle response in subjects exhibiting PPF. With the longer prepulse to pulse ISI, PPF is thought to be generated by a different mechanism than PPI that is automatic sensorimotor gating of unwanted information or response (Graham, 1975) . PPF is an orienting or attentional mechanism by which a prepulse stimulus leads to a stronger startle response (Filion et al, 1993; Hazlett et al, 1998; Wynn et al, 2004) . One of the consistent nicotinic effects mediated by the nicotinic cholinergic system is the enhancement of orienting and attention (eg Witte et al, 1997; Levin et al, 2006) . In our study nicotine did not increase facilitation of startle response but rather led to increased inhibition, similar to its effect in the 120 ms condition. This effect appeared more robust in patients compared to controls, even though statistically there was no significant drug by diagnosis interactions, which may be due to the small sample size and thus insufficient power in this comparison. The current 4500 ms ISI paradigm did not generate PPF in many subjects, limiting our ability to confidently interpret these results. Further studies are needed to carefully examine the effects of nicotine on PPF.
The preliminary analysis of gender effects suggested that there was more nicotinic PPI enhancement in female patients than in male patients. This is consistent with a previous animal study showing that in rat strain that are responsive to nicotinic modulation of PPI, female rats have more robust nicotinic enhancement compared to male rats (Faraday et al, 1999) . Women were also shown to be more susceptible to the PPI-disruptive effects by smoking withdrawal (Della Casa et al, 1998). Swerdlow et al showed that there was a gender difference on baseline PPI, which appeared to be unrelated to smoking (Swerdlow et al, 1999) . There was no significant gender main effect on PPI in our sample. Some of the gender effects on nicotine response are likely mediated by hormonal variations during the menstrual cycle (Swerdlow et al, 1997; Epperson et al, 2005) , which was not recorded in our study. Additional studies are needed to clarify the mechanism for the potential gender and nicotine interaction. Interestingly, studies on other cognitive performance have also noted stronger nasal spray nicotinic effect in female patients than in male patients (Myers et al, 2007) .
Plasma nicotine and CO levels were not collected. Nicotine has a half-life of 1 h. A 3-3.5 h abstinence should reduce the nicotine level by 3-4 half-life cycles, allowing PPI being tested at residual nicotine level. Optimally, the residual nicotine level from cigarette smoking should not reach 0 or at least not reach 0 for prolonged period of time because PPI is very sensitive to nicotine withdrawal (eg Kumari et al, 1996; Kumari and Gray, 1999) . Therefore, we chose the window of 3-3.5 h after the last cigarette for PPI testing. Ideally nicotine level could be drawn prior to each testing to confirm that only low residual level of nicotine was present during PPI testing. This was not done in this study and was a limitation of the study. We also allowed subjects to smoke ad lib prior to arm 1 and arm 2, because we did not believe that an exact smoking pattern for all subjects could be reliably enforced in an outpatient setting. This was another limitation of the study, but may not be severe in a within-subject, crossover design since a subject should have similar smoking pattern before each arm. In addition, we did partially control for smoking pattern by observing the use of the last cigarette and stipulating the interval between the last cigarette and the onset of PPI testing.
In conclusion, nicotine nasal spray improves acoustic PPI in schizophrenia patients. It is not clear which nAChRs subtypes are responsible for this effect. In rodents, a4b2 subunit of nAChRs, but not a7, appears to regulate acoustic PPI (Schreiber et al, 2002) . However, there is strong evidence suggesting that a7 nAChR (for a recent review see Martin and Freedman, 2007) and to a lesser extent a4b2 nAChR (Breese et al, 2000; Durany et al, 2000; Marutle et al, 2001; Faraone et al, 2004; De Luca et al, 2006) are involved in the pathology of schizophrenia. Subtype-specific nAChRs compounds are now becoming available for human studies. Results from the current study encourage retesting of nicotinic effects on PPI in schizophrenia using more selective nAChR subtype agents.
